Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14165295 | 0.76 | F2 (0.52) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL16298358 | 0.76 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL3107462 | 0.73 | F2 (0.46) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL6491985 | 0.69 | F2 (0.53) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL183325 | 0.67 | F2 (1.00) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL21661932 | 0.67 | F2 (0.56) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL22490111 | 0.67 | F2 (0.50) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL2740890 | 0.66 | SIGMAR1 (0.46) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL10331920 | 0.63 | F2 (0.65) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL22490182 | 0.62 | F2 (0.57) | F2PRSS1PRSS2PRSS3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | F2 3843/4885PRSS1 2389/4885PRSS2 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.